• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    11/28/23 2:44:53 PM ET
    $ALLG
    $ARGX
    $AVO
    $BDRX
    Automotive Aftermarket
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLG alert in real time by email

    Shares of SenesTech, Inc. (NASDAQ:SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.

    SenesTech company priced a public offering of around 3.8 million shares of common stock at $1.30 per share, alongside warrants for additional shares.

    SenesTech shares declined 50.3% to $0.9189 on Tuesday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • IceCure Medical Ltd (NASDAQ:ICCM) jumped 90% to $1.44 after the company announced the latest release of a study in a series of independent studies of ProSense published in peer-reviewed journals demonstrating safety and efficacy.
    • RedHill Biopharma Ltd. (NASDAQ:RDHL) gained 90% to $1.90. Redhill Biopharma announced the FDA has granted five years' market exclusivity for Talicia.
    • HNR Acquisition Corp (NASDAQ:HNRA) gained 67% to $2.89 after the company gave a business update.
    • Fusion Fuel Green PLC (NASDAQ:HTOO) rose 39.6% to $1.25.
    • Carbon Revolution Public Limited Company (NASDAQ:CREV) gained 30% to $33.55 after Craig-Hallum initiated coverage on the stock with a Buy rating and a $84 price target.
    • ESGL Holdings Limited (NASDAQ:ESGL) gained 29.6% to $1.1590 as the company disclosed a multi-year contract renewal with Singapore Refining Company Private Limited.
    • Bitfarms Ltd. (NASDAQ:BITF) gained 24.5% to $1.3200. The company announced upgrades for its mining fleet.
    • Arcimoto, Inc. (NASDAQ:FUV) rose 23.7% to $1.0892.
    • Gyre Therapeutics, Inc. (NASDAQ:GYRE) gained 23.5% to $25.85.
    • Farfetch Limited (NYSE:FTCH) gained 21.9% to $2.0850 following a report suggesting the company's founder may be in talks to take the company private.
    • Avidity Biosciences, Inc. (NASDAQ:RNA) surged 21.3% to $7.47 after the company reported expansion of cardiovascular collaboration with Bristol Myers Squibb.
    • Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) climbed 20.4% to $2.7209.
    • SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) gained 19.1% to $24.73. The FDA approved SpringWorks Therapeutics’ Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who require systemic treatment.
    • PDD Holdings Inc. (NASDAQ:PDD) shares gained 18% to $138.90 following third-quarter results.
    • CleanSpark, Inc. (NASDAQ:CLSK) rose 13.3% to $6.32.
    • Cheche Group Inc. (NASDAQ:CCG) surged 12.3% to $6.17.
    • Clearway Energy, Inc. (NYSE:CWEN) gained 11.4% to $25.48. Clearway Energy will replace Veritiv in the S&P SmallCap 600.
    • LendingClub Corporation (NYSE:LC) climbed 10.6% to $6.17. Piper Sandler initiated coverage on LendingClub with an Overweight rating and announced a price target of $8.
    • Lilium N.V. (NASDAQ:LILM) gained 10.4% to $1.0050. Lilium announced it received EASA Design Organization Approval.
    • Marathon Digital Holdings, Inc. (NASDAQ:MARA) climbed 8.2% to $12.21.
    • The Carlyle Group Inc. (NASDAQ:CG) rose 5.1% to $34.48. Carlyle Group will replace ICU Medical in the S&P MidCap 400, effective prior to the open of trading on Nov. 30.

    Losers

    • Tharimmune, Inc. (NASDAQ:THAR) shares fell 72.8% to $0.9499. Tharimmune priced its $10 million public offering 10 million common shares at $1 per share.
    • Cabaletta Bio, Inc. (NASDAQ:CABA) fell 31.9% to $12.73 after the FDA said it was investigating a risk of T-cell malignancies in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
    • Acelyrin, Inc. (NASDAQ:SLRN) declined 31.6% to $5.94 after the company announced an error in its Phase 2b/3 trial for izokibep. The company said the error has been addressed and the dosing sequence has been fixed.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) fell 31.2% to $3.5195 after the company announced an offering of 1,397,849 Class A units at an assumed public offering price of $2.79 per Class A unit.
    • iBio, Inc. (NASDAQ:IBIO) fell 28% to $0.2078 after the company announced a 20-to-1 reverse stock split.
    • CohBar, Inc. (NASDAQ:CWBR) fell 23.2% to $0.6901.
    • Gracell Biotechnologies Inc. (NASDAQ:GRCL) declined 13.6% to $4.6650. Gracell Biotechnologies recently announced it received FDA clearance of the IND application for the Phase 1/2 clinical trial of FasTCAR-T GC012F for the treatment of refractory systemic lupus erythematosus.
    • Erasca, Inc. (NASDAQ:ERAS) declined 11.6% to $1.98 after announcing program updates.
    • argenx SE (NASDAQ:ARGX) fell 10.5% to $443.67 after the company reported the ADVANCE-SC study evaluating VYVGART Hytrulo in adults with primary immune thrombocytopenia did not meet primary or secondary endpoints.
    • Allego N.V. (NASDAQ:ALLG) declined 9.6% to $1.2650.
    • Luminar Technologies, Inc. (NASDAQ:LAZR) fell 9.6% to $2.3750.
    • Mission Produce, Inc. (NASDAQ:AVO) fell 7.1% to $8.24. Roth MKM maintained Mission Produce with a Buy and lowered the price target from $18 to $12.5.
    • Cool Company Ltd. (NYSE:CLCO) shares fell 5.3% to $12.72 after reporting results for the third quarter.

     

     

    Now Read This: Top 5 Risk Off Stocks Which Could Rescue Your Portfolio This Month

    Get the next $ALLG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLG
    $ARGX
    $AVO
    $BDRX

    CompanyDatePrice TargetRatingAnalyst
    argenx SE
    $ARGX
    3/10/2026Hold → Buy
    Deutsche Bank
    MARA Holdings Inc.
    $MARA
    2/27/2026Buy → Neutral
    H.C. Wainwright
    The Carlyle Group Inc.
    $CG
    2/24/2026$67.00Outperform
    RBC Capital Mkts
    MARA Holdings Inc.
    $MARA
    2/9/2026$8.00Underweight
    Morgan Stanley
    Erasca Inc.
    $ERAS
    1/27/2026$16.00Outperform
    Mizuho
    Bitfarms Ltd.
    $BITF
    1/27/2026$3.00Outperform → Mkt Perform
    Keefe Bruyette
    CleanSpark Inc.
    $CLSK
    1/13/2026$22.50Outperform
    Northland Capital
    CleanSpark Inc.
    $CLSK
    1/8/2026$22.00Buy
    Maxim Group
    More analyst ratings

    $ALLG
    $ARGX
    $AVO
    $BDRX
    SEC Filings

    View All

    SEC Form 6-K filed by ESGL Holdings Limited

    6-K - ESGL Holdings Ltd (0001957538) (Filer)

    3/10/26 4:15:15 PM ET
    $ESGL
    Environmental Services
    Utilities

    SEC Form SC TO-C filed by Clearway Energy Inc.

    SC TO-C - Clearway Energy, Inc. (0001567683) (Subject)

    3/9/26 5:26:33 PM ET
    $CWEN
    Electric Utilities: Central
    Utilities

    SEC Form PRE 14A filed by Clearway Energy Inc.

    PRE 14A - Clearway Energy, Inc. (0001567683) (Filer)

    3/9/26 5:23:55 PM ET
    $CWEN
    Electric Utilities: Central
    Utilities

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO Sanborn Scott

    4 - LendingClub Corp (0001409970) (Issuer)

    3/9/26 8:32:32 PM ET
    $LC
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by SVP, Corporate Controller Stack Fergal

    4 - LendingClub Corp (0001409970) (Issuer)

    3/9/26 8:30:56 PM ET
    $LC
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Bank - Chief Lending Officer Mattics Steven C

    4 - LendingClub Corp (0001409970) (Issuer)

    3/9/26 7:26:34 PM ET
    $LC
    Finance: Consumer Services
    Finance

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/6/26 5:40:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ALLG
    $ARGX
    $AVO
    $BDRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

    CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Tuesday, March 17, 2026. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Tuesday, March 17, 2026, at 11:00 am EDTUS: 1-888-407-2553Is

    3/10/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

    Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015's promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, which will

    3/10/26 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearway Energy, Inc. Seeks Shareholder Approval at Annual Meeting to Simplify Public Share Class Structure

    PRINCETON, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Clearway Energy, Inc. (NYSE:CWEN, CWEN.A)) (the "Company") announced today that its Board of Directors (the "Board") has approved a proposal to be submitted for stockholder approval at its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") to simplify its public share class structure into a single share class. The Board has approved a proposal to amend and restate the Company's certificate of incorporation (the "Charter Amendment") that would convert each share of the Company's Class A common stock, par value $0.01 per share (the "Class A common stock"), into one share of the Company's Class C common stock, par value $0.01 p

    3/9/26 5:07:00 PM ET
    $CWEN
    Electric Utilities: Central
    Utilities

    argenx upgraded by Deutsche Bank

    Deutsche Bank upgraded argenx from Hold to Buy

    3/10/26 3:28:52 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MARA Holdings Inc. downgraded by H.C. Wainwright

    H.C. Wainwright downgraded MARA Holdings Inc. from Buy to Neutral

    2/27/26 11:05:23 AM ET
    $MARA
    EDP Services
    Technology

    RBC Capital Mkts initiated coverage on Carlyle Group with a new price target

    RBC Capital Mkts initiated coverage of Carlyle Group with a rating of Outperform and set a new price target of $67.00

    2/24/26 7:47:48 AM ET
    $CG
    Investment Managers
    Finance

    November 27, 2023 - FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

    For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor

    11/27/23 5:34:21 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for OGSIVEO issued to SPRINGWORKS THERAPEUTICS INC

    Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity

    11/27/23 5:34:04 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Leadership Updates

    Live Leadership Updates

    View All

    IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

    Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technolo

    2/9/26 4:30:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fusion Fuel Green PLC

    SC 13G/A - Fusion Fuel Green PLC (0001819794) (Subject)

    12/11/24 4:02:05 PM ET
    $HTOO
    Industrial Machinery/Components
    Energy

    SEC Form SC 13D filed by Fusion Fuel Green PLC

    SC 13D - Fusion Fuel Green PLC (0001819794) (Filed by)

    12/6/24 6:06:39 PM ET
    $HTOO
    Industrial Machinery/Components
    Energy

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Financials

    Live finance-specific insights

    View All

    IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

    CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Tuesday, March 17, 2026. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Tuesday, March 17, 2026, at 11:00 am EDTUS: 1-888-407-2553Is

    3/10/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Clearway Energy, Inc. Seeks Shareholder Approval at Annual Meeting to Simplify Public Share Class Structure

    PRINCETON, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Clearway Energy, Inc. (NYSE:CWEN, CWEN.A)) (the "Company") announced today that its Board of Directors (the "Board") has approved a proposal to be submitted for stockholder approval at its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") to simplify its public share class structure into a single share class. The Board has approved a proposal to amend and restate the Company's certificate of incorporation (the "Charter Amendment") that would convert each share of the Company's Class A common stock, par value $0.01 per share (the "Class A common stock"), into one share of the Company's Class C common stock, par value $0.01 p

    3/9/26 5:07:00 PM ET
    $CWEN
    Electric Utilities: Central
    Utilities

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials